Press Release - Company Data

CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
Posted 2014-09-03 00:02NAI Editing
today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunothe

CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial
Posted 2014-08-01 00:14NAI Editing
today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer tria

CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
Posted 2014-07-22 00:09NAI Editing
today announced that Turkey’s Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI’s global pivotal Phase III Head and Neck Cancer clinical trial of its investigational ca

CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
Posted 2014-07-17 00:28NAI Editing
today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunothe

CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
Posted 2014-07-15 00:17NAI Editing
announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (N

CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial into Austria
Posted 2014-07-08 00:04NAI Editing
today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company’s Phase III Head and Neck Cancer clinica

CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Posted 2014-06-02 23:45NAI Editing
today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial

CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
Posted 2014-06-01 23:55NAI Editing
today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company’s Phase III Head and Neck Cancer clinical tria

CEL-SCI Corporation Reports Second Quarter Fiscal 2014 Financial Results
Posted 2014-05-12 23:50NAI Editing
today reported financial results for the quarter ended March 31, 2014. Recent key corporate and clinical developments include:

CEL-SCI Reports April 2014 is Another Record Month for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Posted 2014-04-30 23:36NAI Editing
today announced that during the month of April 2014 the Company enrolled 21 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial f